International Stem Cell

US: ISCO

$10m market cap

$1.48 last close

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson’s disease.

Investment summary

International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of $2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). At the six-month time point, the percentage OFF-Time, a key endpoint for PD treatment, decreased an average of 49% for the second cohort of patients, compared to 24% for the first, with four patients in each cohort.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2016A 7.2 (4.5) (4.9) (152.07) N/A N/A
2017A 7.5 (4.6) (4.9) (118.86) N/A N/A
2018E 11.5 (2.8) (3.2) (50.00) N/A N/A
2019E 13.5 (5.9) (7.0) (104.69) N/A N/A
Last updated on 15/02/2019
Industry outlook

ISCO’s technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.

Last updated on 15/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (US$m) 0.9
Forecast gearing ratio (%) 27
Price performance
%
1m
3m
12m
Actual (3.3) (9.8) (6.3)
Relative* (9.0) (11.2) (7.8)
52-week high/low US$1.8/US$1.4
*% relative to local index
Key management
Andrey Semechkin CEO and Co-Chairman
Donald Wright Co-Chairman
Jennifer Stephens Acting CFO
Russell Kern Executive Vice President, CSO